Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-04-24
2000-06-20
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514578, 514725, 514730, 514739, 424523, 426 72, 426601, 426602, 426656, 426800, 426801, A23J 316, A61K 3817
Patent
active
060778288
ABSTRACT:
The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of .omega.-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.
REFERENCES:
patent: 4615839 (1986-10-01), Seto
patent: 5223285 (1993-06-01), DeMichele et al.
patent: 5308832 (1994-05-01), Garleb et al.
patent: 5330972 (1994-07-01), Cope
patent: 5385740 (1995-01-01), Tisdale et al.
patent: 5393784 (1995-02-01), Richardson
patent: 5431925 (1995-07-01), Ohmori et al.
patent: 5444054 (1995-08-01), Garleb et al.
patent: 5457130 (1995-10-01), Tisdale
Utesjev et al. "immunomodulating and antioxidant effect of beta-carotene andessentiale in disturbed lipid metabolism" CA 129:184101, 1998.
Cho et al. "Lipid peroxidation and antioxidant status is affected fy different vitamin E levels when feeding fish oil" CA 120:132920, 1994.
Abstract of DE 3901048 Derwent 90-225190 (1990).
Keller, Ulrich, Pathophysiology of cancer cachexia, Supportive Care in Cancer (1993) 1:209-294.
Derwent -90-225190 (1990).
Derwent -Abstract 010905121 (1996).
Ottery, Faith D., M.D. Cancer Cachexia, Cancer Practice, Mar./Apr. 1994, vol. 2, No.2., pp. 123-131.
Ottery, Faith D., M.D., Supportive Nutrition to Prevent Cachexia and Improve Quality of Life, Seminars in Oncology, vol. 22, No. 2, Supplement 3 (Apr.), 1995, pp. 98-111/
Kern, Kenneth, M.D., et al., Cancer Cachexia, Journal of Parental and Enteral Nutrition, vol. 12, No. 3, pp. 286-294 (1988).
Heber, David, M.D., Ph.D., et al., Hormonal and Metabolic Abornalities in the Malnourished Cancer Patient; Effects on Host-Tumor Interaction, Journal of Parenteral and Enteral Nutirition, vol. 16, No. 6, Supplement, pp. 60S-64S (1992).
McNamara, Michael J., M.D., et al. Cytokines and Their Role in the Pathophysiology of Cancer Cachexia, Journal of Parenteral and Enteral Nutrition, vol. 16, No. 6, Supplement, pp. 50S-55S (1992).
Tisdale, M.J., Cancer Cachexia, Anti Cancer Drugs, vol. 4, pp. 113-125 (1993).
Bozzetti, Federico, M.D., Effects of Artificial Nutrition on the Nutritional Status of Cancer Patients, Journal of Parenteral and Enteral Nutrition, vol. 13, No. 4 pp. 406-420 (1989).
Derwent -011043748 (1996).
Derwent -011043746 (1996).
Derwent -008405601 (1990).
Todorov, Penio, et al., Characterization of a cancer cachectic factor, Nature, vol. 379, Feb. 22, 1996, pp. 739-742.
Wigmore, Stephen, et al., The Effect of Polyunsaturated Fatty Acids on the Progress of Cachexia in Patients with Pancreatic Cancer, Nutrition, vol. 12, No. 1, 1996, pp. S27-S30.
Tisdale, Michael J., et al., Inhibition of Lipolysis and Muscle Protein Degradation by EPA in Cancer Cachexia, Nutrition, vol. 12, 1996, pp. S31-S33.
Henderson, Robin A., et al., Effect of Fish Oil on the Fatty Acid Composition of Human Milk and Maternal and Infant Erythrcytes, Lipids, vol. 27, No. 11 (1992), pp. 863-869.
Tisdale, Michael J., et al., Inhibition of Weight Loss by .omega.-3 Fatty Acids in an Experimental Cachexia Model, Cancer Research 50, 5022-5026, Aug. 15, 1990.
Dinarello, Charles A., et al., Interleukin-1, Anorexia, and Dietary Fatty Acids, Annals of The New York Academy of Sciences, vol. 587, pp. 332-338 (1990).
Build Bulk and Muscle for that Competitive Edge, Herbalife Advertisement, Los Angeles, California, 90080-00210, 1996.
Cangiano, C., et al., Plasma and CSF Tryptophan in Cancer Anorexia, J Neural Transm (GenSect) 1990, 81:225-233.
Rossi-Fanelli, F., M.D., et al., Increased Availability of Tryptophan in Brain as Common Pathogenic Mechanism for Anorexia Associated with Different Diseases, Nutrition, vol. 7 No. 5, Sep./Oct. 1991.
Rossi-Fanelli, Filippo, et al., Plasma Tryptophan and Anorexia in Human Cancer, Eur J Cancer Clin Oncol, vol. 22, No. 1 pp. 89-95, 1986.
Krause, Rudolf, et al., Brain Tryptophan and the Neoplastic Anorexia-Cachexia Syndrome, Cancer, Sep. 1979, 44: pp. 1003-1008.
Meguid, Michael, et al., The Early Cancer Anorexia Paradigm: Changes in Plasma Free Tryptophan and Feeding Indexes, Journal of Parenteral and Enteral Nutrition, vol. 16, No. 6, Supplement, pp. 56S-59S (1992).
Anticancer Research, vol. 14, 1994, pp. 1451-1455, XP002035801, C. Cangiano, et al., "Cytokines, Tryptophan and Anorexia in Cancer Patients Before and After Surgical Tumor Ablation".
Abbruzzese Bonnie Chandler
Cope Frederick Oliver
DeMichele Stephen Joseph
McCamish Mark Anthony
Abbott Laboratories
Brainard Thomas D.
Chang Ceila
Dixon J. Michael
LandOfFree
Method for the prevention and treatment of cachexia and anorexia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the prevention and treatment of cachexia and anorexia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the prevention and treatment of cachexia and anorexia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1853797